We are a leading clinical-stage precision oncology company focused on synthetic lethality.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines.
Our goal is to be the leading biopharmaceutical company developing precision oncology, small molecule therapies based on synthetic lethality.
We are a leader in developing innovative synthetic lethality therapies and have built our SNIPRx platform based on three primary pillars:
- Identify novel synthetic lethality targets using our proprietary, genome-wide, CRISPR-enabled screening technology against clinically relevant genomic alterations in tumors with high unmet medical need
- Design and synthesize potent and selective small molecule inhibitors of these targets
- Expand beyond the initial target population based on the additional genomic alterations identified by our proprietary STEP2 screens that are synthetic lethal with our inhibitors